Macular recovery after phacoemulsification

Article

Further studies needed on the reversible post-op changes in the macula

In a presentation during the Complex Cases session at the annual ESCRS congress in Vienna, Austria, Dr Dušica Pahor (Department of Ophthalmology, University Clinical Centre Maribor, Slovenia Faculty of Medicine, Slovenia) revealed why there is a need to continue studying the recovery of a patient's macular post-cataract surgery.

The method

Evaluation of the macular thickness and volume were performed using the Stratus OCT (Carl Zeiss Meditec Ophthalmic Systems Inc., Dublin, California, USA) and measurements were taken 1-day preop and then 1-day, 1-, 3- and 6-months postop. "We used a 'Fast Macular Thickness Map' scan protocol to obtain six macular scans that were 6 mm long and centred on the fovea equally set at 30° apart," explained Dr Pahor. "We imaged nine regions of the macular, the fovea (F), temporal inner macula (TIM), superior inner macula (SIM), nasal inner macula (NIM), inferior inner macula (IIM), temporal outer macula (TOM), superior outer macula (SOM), nasal outer macula (NOM) and inferior outer macula (IOM)." The statistical analysis was performed using the SPSS for Windows 19.0.

Further to this Dr Pahor explained that a complete ophthalmic evaluation was performed on all patients postoperatively. "OCT measurements were taken in the foveal and perifoveal regions 3-months postop and compared with those taken at 1-month post-op," she said.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.